This funding opportunity supports research projects aimed at optimizing and translating genomic and biologic therapeutic candidates for Alzheimer’s Disease-Related Dementias (ADRD). It covers the full translational pipeline including therapeutic design refinement, manufacturability, pharmacology, toxicology, biodistribution, in vivo efficacy, regulatory data generation, and early clinical studies. Priority areas include frontotemporal degeneration, Lewy body dementia, and vascular contributions to cognitive impairment and dementia.
Eligible applicants include a wide range of U.S. government entities, educational institutions, nonprofits, for-profit organizations, tribal governments, and certain non-U.S. entities. Specific eligibility details are provided in the announcement.
